newsfilter
← Latest News
GlobeNewswire·

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for